AsiFlyer Biotechnology

AsiFlyer Biotechnology (also known as Ruoyi Bio) is an innovative biopharmaceutical company specializing in the development of recombinant protein drugs and advanced macromolecular drug delivery technologies. Spun out of ShanghaiTech University, the company utilizes its proprietary Zinc Finger Proteins (ZFPs) drug delivery platform and the insect cell-baculovirus expression system (InsBac™) to engineer next-generation therapeutics. Its lead clinical candidate, CB2201, is a third-generation recombinant botulinum toxin type A currently in Phase 2 clinical trials for aesthetic and therapeutic indications, including glabellar lines, upper limb spasticity, and masseter hypertrophy. AsiFlyer is also pioneering AI-driven protein design platforms (PointMut™ and ClusMine™) to develop fourth-generation botulinum toxin products with reduced immunogenicity and enhanced safety profiles. Headquartered in Suzhou with an R&D center in Shanghai, the company has established a 10,000-square-meter GMP-compliant commercial manufacturing facility in Kunshan.